Culture-Dependent Bioprospecting of Bacterial Isolates From the Canadian High Arctic Displaying Antibacterial Activity

Evangelos Marcolefas¹, Tiffany Leung², Mira Okshevsky¹, Geoffrey McKay², Emma Hignett², Jérémie Hamel¹, Gabriela Aguirre¹, Olivia Blenner-Hassett¹, Brian Boyle³, Roger C. Lévesque³, Dao Nguyen², Samantha Gruenheid²* and Lyle Whyte¹ *

¹ Department of Natural Resource Sciences, McGill University, Sainte-Anne-de-Bellevue, QC, Canada, ² Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada, ³ Institute for Integrative Systems Biology, Université Laval, Quebec City, QC, Canada

The goal of this study was to isolate, screen, and characterize Arctic microbial isolates from Expedition Fjord, Axel Heiberg Island, Nunavut, Canada capable of inhibiting the growth of foodborne and clinically relevant pathogens. Arctic bacteria were isolated from twelve different high Arctic habitats pertaining to active layer permafrost soil, saline spring sediments, lake sediments, and endoliths. This was achieved using (1) the cryo-iPlate, an innovative in situ cultivation device within active layer permafrost soil and (2) bulk plating of Arctic samples by undergraduate students that applied standard culturing methods. To mitigate the possibility of identifying isolates with already-known antibacterial activities, a cell-based dereplication platform was used. Ten out of the twelve Arctic habitats tested were found to yield cold-adapted isolates with antibacterial activity. Eight cold-adapted Arctic isolates were identified with the ability to inhibit the entire dereplication platform, suggesting the possibility of new mechanisms of action. Two promising isolates, initially cultured from perennial saline spring sediments and from active layer permafrost soil (Paenibacillus sp. GHS.8.NWYW.5 and Pseudomonas sp. AALPS.10.MNAAK.13, respectively), displayed antibacterial activity against foodborne and clinically relevant pathogens. Paenibacillus sp. GHS.8.NWYW.5 was capable of inhibiting methicillin resistant and susceptible Staphylococcus aureus (MRSA and MSSA), Listeria monocytogenes, Salmonella enterica and Escherichia coli O157:H7. Pseudomonas sp. AALPS.10.MNAAK.13 was observed to have antagonistic activity against MRSA, MSSA, Acinetobacter baumanii, Enterococcus faecium, and Enterococcus faecalis. After whole genome sequencing and mining, the genome of Paenibacillus sp. GHS.8.NWYW.5 was found to contain seven putative secondary metabolite biosynthetic gene clusters that displayed low homology (<50% coverage, <30% identity, and e-values > 0) to clusters identified within the genome of the type strain pertaining to the same species. These findings suggest that cold-adapted Arctic microbes may be a promising source of novel secondary metabolites for potential use in both industrial and medical settings.

Keywords: Arctic, bioprospecting, antibiotics, secondary metabolites, microbial cultivation
INTRODUCTION

The rise of antibiotic resistance is one of the most urgent challenges the world currently faces. Antimicrobial resistance has steadily increased in clinical settings (Bitnun and Yeh, 2018). We are on the cusp of returning to a pre-antibiotic world in which common infections and minor injuries will once again become deadly (Laxminarayan et al., 2013; Ferri et al., 2017; Pawar et al., 2017). Simultaneously, natural product discovery efforts on the part of the pharmaceutical industry have largely dwindled since the end of the 20th century (Baker et al., 2007). Given that the current arsenal of effective antibiotics is decreasing, innovative discovery workflows for the identification of novel antibiotics are needed.

Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterococcus species (ESKAPE) are recognized by the Infectious Disease Society of America as the bacteria posing the most significant risk to public health in the United States (Boucher et al., 2009). The ESKAPE pathogens are responsible for the majority of nosocomial infections in the United States, with an estimated 722,000 infections acquired in 2011 (Magill et al., 2014). Of particular concern are the increasing levels of antibiotic resistance occurring in these organisms, especially methicillin-resistant S. aureus (MRSA), vancomycin-resistant E. faecium, and fluoroquinolone-resistant P. aeruginosa (National Nosocomial Infections Surveillance System, 2004). MRSA infections are now responsible for more deaths in U.S. hospitals than HIV/AIDS and tuberculosis combined (Klevens et al., 2006; Boucher and Corey, 2008).

Many of the antibiotics currently in use are secondary metabolite natural products from soil bacteria, particularly from the Streptomyces genus. Since the pioneering experiments of Selman Waksman in the 1940s, this resource has been extensively studied (Waksman and Woodruff, 1940; Schatz et al., 1944). New approaches or modification to existing methods may be necessary to increase the probability of finding novel compounds. Once an isolate with antibiotic activity is identified, a “dereplication” procedure is required to avoid the re-discovery of already-known antibiotics. Compound extraction, purification and biochemical analyses are costly and technically challenging. Instead, we have employed a cell-based dereplication platform (Cox et al., 2017), in which isolates are tested for inhibitory activity against a panel of Escherichia coli strains expressing specific antibiotic resistance genes. The presence of inhibitory activity against all dereplication strains that comprise the Antibiotic Resistance Platform (ARP) suggests that the isolate produces antimicrobial secondary metabolite(s) with a potentially novel mechanism of action. As an additional dereplication measure, genomic sequencing and in silico genome mining could be used to prioritize isolates for downstream testing. Microbial genomic sequences could be mined in silico to detect secondary metabolite biosynthetic gene clusters (BGCs) using open source web-based pipelines such as the antibiotics and secondary metabolite analysis shell (antiSMASH) (Blin et al., 2019). Once microbial genomes have been mined, isolates can be prioritized on the basis of low BGC sequence homology to known clusters (Medema et al., 2015).

In the search for new antibiotics, interest has been growing in underexplored environments such as marine systems (Jang et al., 2013; Machado et al., 2015) and the deep biosphere (Orsi et al., 2013). The Canadian high Arctic is characterized by extreme environmental conditions such as high salt and prolonged subzero temperatures. The unique ecological niches (i.e., hypersaline springs, permafrost and endoliths) of the high Arctic harbor diverse microbial communities which remain largely unexplored (Perreault et al., 2007, 2008; Steven et al., 2007; Lay et al., 2013). Recent macro- and microdiversity studies have revealed that Arctic microorganisms do not always follow the latitudinal diversity paradigm, which states that diversity decreases towards the poles (Gregory et al., 2019). Arctic environments have been observed to be a cradle for microbial diversity (Gregory et al., 2019). Due to the rich microbial diversity and unique selective pressures experienced by the Arctic microbiome, we hypothesize that this extreme environment has potential for harboring novel antibacterial secondary metabolites. Previous bioprospecting studies conducted in polar cryohabitats have successfully identified microbial isolates expressing new natural products and encoding unknown secondary metabolite BGCs (Mitova et al., 2005; Tedesco et al., 2016; Dhaneesha et al., 2017). One such example includes the discovery of Streptomyces artesiae MCCB 248 isolated from sediments in the Arctic fjord Kongsfjorden. This isolate was shown to produce secondary metabolites with anticancer properties and was found to encode unique polyketide synthetase (PKS) and non-ribosomal peptide (NRP) genes (Dhaneesha et al., 2017). Isolating secondary-metabolite-producing microbes from Arctic environments has the additional benefit of yielding strains with inhibitory activity at cold temperatures. Cold-active antimicrobial enzymes, such as cold-active alkaline phosphatases with antibiofilm activity, represent appealing biopreservatives for food processing industries since they can extend the shelf life of refrigerated consumables (Balabanova et al., 2017).

Identifying and isolating new antibacterial secondary metabolites often depends on cell-based screening of cultivable strains. Co-culture assays are known to activate silent BGCs in antibiotic-producing strains that would not be expressed in pure culture (Zarins-Tutt et al., 2016). Unfortunately, only a small percentage of all microbial species can be isolated using classic cultivation techniques (Winterberg, 1898; Ward et al., 1990). Innovative cultivation techniques are expanding the portion of cultivable isolates that could be phenotypically screened using cell-based assays (Vartoukian et al., 2010). The efficacy of such in situ cultivation techniques for drug discovery is illustrated by the recent discovery of the antibiotic Teixobactin, derived from an ichip isolate (Ling et al., 2015). Based on the initial design of the ichip, the cryo-iPlate prototype designed and implemented by Goordial et al. (2017) was the first in situ cultivation device deployed in the Arctic. Here, a re-designed and updated version of the cryo-iPlate is described for the first time and is used to isolate Arctic microorganisms for antibacterial screening. In addition to sampling unique ecological habitats and implementing the new cryo-iPlate cultivation device, the bioprospecting workflow described here uses a crowd-sourced screening approach first developed by Jo Handelsman at...
Yale University in 2012, which harnesses the manpower of undergraduate microbiology teaching labs to screen bacterial isolates for antibiotic activity (Davis et al., 2017).

Here, we employed two cultivation methods to isolate and then screen bacteria derived from Canadian high Arctic habitats for antibacterial activities (Figure 1). Arctic isolates were screened for antibiotic activity against a collection of both foodborne and clinical pathogens. Cold-adapted antibiotic-producing bacteria were derived from Arctic permafrost, saline spring sediments, and cryptoenoliths suggesting that high Arctic environments could be a potentially untapped source of novel antibacterial secondary metabolites.

**MATERIALS AND METHODS**

**Sampling Arctic Microbiomes**

The various soil and rock samples used in this study were collected within the vicinity of the McGill Arctic Research Station (MARS) on Axel Heiberg Island, Nunavut, in the Canadian high Arctic. The sediment, soil and rock samples were collected for crowdsourced bulk plating whereas the in situ cryo-iPlate cultivation approach was only applied to active layer permafrost soil (described below). Sediments from spring outflow channels and soil in this study were collected with an ethanol-sterilized spatula used to exhume the first 15 cm of soil/sediment horizons. Rocks with visible lithic microbial biomass were sampled by breaking large rocks into smaller pieces using an ethanol-sterilized hammer and chisel. All rock and soil samples were collected in sterile WhirlPak bags and stored in coolers kept at 5°C until returned to McGill University. Upon return to the laboratory, all samples were stored at 5°C.

**Cryo-iPlate Procedures**

The cryo-iPlate design was based on the Nichols et al. (2010) ichip and the Goordial et al. (2017) cryo-iPlate prototype (Nichols et al., 2010; Goordial et al., 2017). It was designed using the Rhino 6 software and 3D-printed at Fablab Inc., Montreal, using durable PC-ISO polycarbonate plastic. Previous prototypes of the cryo-iPlate such as the one described in Goordial et al. (2017), consisted of empty pipette boxes that were not as durable in the field. The dimensions of the improved version of the cryo-iPlate described herein are 15 cm by 12 cm. It features 160 wells (as opposed to 96 in previous prototypes) that are 0.5 cm wide and deep. The wells of the central plate were filled with 2% w/v gellan gum (Alfa Aesar) prior to being deployed in the field. Based on previous studies of total microbial counts in active layer permafrost at the MARS study site, dilutions of the soil were made in the field using sterile water (Wilhelm et al., 2011). This device was only applied to active layer permafrost. Each individual well of the central plate was inoculated in the field with 10 µl of diluted soil containing ∼1–10 microbial cells. The top and bottom layers were overlaid with sterile semi-permeable 0.03 µm-pore-size polycarbonate membranes (Whatman™, GE Healthcare Life Sciences) and were glued using a silicon adhesive (DuPont). The assembly of three plates was then screwed together using eight stainless steel 10–24 screws and left to incubate in situ. After incubating in the field for 10 days, the cryo-iPlate was collected in a large sterile WhirlPak sampling bag along with the soil in which it was incubating. The assembly was stored in a cooler at 5°C during transport back to McGill University where it was subsequently incubated ex situ at 5°C for 3 months before being disassembled for subculturing. After disassembling the cryo-iPlates, well contents from the central plate were pushed into individual Eppendorf tubes containing 0.1% w/v pyrophosphate using sterile 1000 µl
pipette tips (Diamed Canada). Eppendorf tubes containing well contents from the cryo-iPlate in buffer solution were vortexed for 30 s and 100 µL of the solution was used to inoculate plates of 1/2 Reasoner’s 2A (R2A) broth media solidified with 2% gellan gum (Alfa Aesar). The plates were incubated at room temperature for 2 weeks. Morphologically distinct colonies (selected based on distinct colony form, elevation, margin, size, texture and color) that grew on the 1/2 R2A plates were subcultured three times to attain clonal populations before being screened against the ES KAPE relative strains.

Crowdsourced Screening of Isolates Against ES KAPE Pathogen Relatives

The twelve sample types described in Table 1 were processed by students in the Introduction to Microbiology Laboratory Course at McGill University in the following manner. One gram of sample was serially diluted in sterile water to 10⁻³, and 100 µL of each dilution were spread onto lysogenic broth (LB) plates solidified with gellan, tryptic soy agar (TSA) (10% or 0.1%), potato dextrose agar or sheep blood agar. Each student pair participating in the course was provided with one of the Arctic samples and was allowed to select one of the aforementioned culturing media to increase the diversity of isolates obtained. Plates were incubated for 1 week at room temperature and morphologically distinct colonies were picked (selected based on colony form, elevation, margin, size, texture and color) and re-streaked to produce libraries of clonal populations. Isolates were screened against ES KAPE pathogen relatives (Supplementary Table S1) using the spread-patch technique (Figure 2A). Since antibiotic activity screening is performed in teaching labs, isolates were tested against non-pathogenic relatives of high priority threat pathogens. A diluted suspension of tester bacteria was evenly spread across on agar plate, and the Arctic isolates spotted on top. Plates were incubated for 1 week at room temperature and observed for a zone of pathogen inhibition surrounding isolates. All isolates that produced a zone of inhibition were given a name and stored as glycerol freezer stocks and selected for dereplication (Figure 1). If isolates were surrounded by a visually discernible zone of clearance devoid of any tester strain growth, then they were deemed to have positive antibacterial activity (Figure 2A).

Taxonomic Identification of Isolates

Isolates from the cryo-iPlate and from the crowdsourced bulk soil plating that displayed zones of inhibition against at least one of the ES KAPE relatives were selected for 16S rRNA gene sequencing. Colony PCR was first conducted to amplify the 16S rRNA gene using the 27F (forward) bacterial primer: 5′-AGAGTTACCTTGTTACGACTT-3′ and the 1492R (reverse) bacterial primer: 5′-GGTACCTTGTACGACTT-3′. The 16S rDNA amplification PCR reaction cycling program consisted of: (1) 95°C for 7 min, (2) 94°C for 45 s, (3) 55°C for 45 s, (4) 72°C for 1 min, (where steps 2 to 4 were repeated 30 times), (5) 72°C for 10 min. PCR products from the cryo-iPlate and from the bulk soil plating were sent for Sanger sequencing at the Plateforme d’Analyses Genomiques center at Laval University and the McGill University and at the Génome Québec Innovation Centre (respectively). All generated sequences were manually curated using 4Peaks software1 where sequence segments with an average Q > 40 were used as queries against the EzBioCloud database for taxonomical identification (Yoon et al., 2017).

Dereplication Platform

Isolates that demonstrated antibacterial activity against at least one ES KAPE relative were tested against a dereplication platform described in Supplementary Table S2, and provided by the Wright lab at McMaster University (Cox et al., 2017). This dereplication platform consists of two parental strains: Wild type E. coli BW25113, and E. coli ΔbamB ΔtolC BW25113 harboring mutations to increase outer membrane permeability and decrease efflux pump activity, thereby increasing its susceptibility to antibiotics. In all cases except the flaB mutant, the Wright lab transformed these parent strains with plasmids harboring antibiotic resistance genes. Isolates were screened against the dereplication strains using the wagon-wheel assay, in which dereplication strains were streaked in a circle to form the “wheel” on LB plates, and Arctic isolates were streaked across the wheel to form “spokes” (Figure 2B). Plates were incubated for 1 week at room temperature and it was subsequently observed in which cases the isolates were able to inhibit the growth of the dereplication strain. Isolates able to inhibit the growth of all dereplication strains were considered to have “passed.”

Screening Arctic Isolates That Passed the ARP Against ES KAPE Pathogens

Arctic isolates that passed the ARP were screened for inhibitory activities against a panel of ES KAPE pathogens, namely Enterobacter cloacae (strain CO794 provided by the G. Wright laboratory), methicillin-resistant S. aureus (MRSA) (ATCC 43300), methicillin-susceptible S. aureus (MSSA) (ATCC 29213), K. pneumoniae (clinical strain HO132323 provided by the G. Wright laboratory), Acinetobacter baumannii ABS075, P. aeruginosa WT PAO1, E. faecium (ATCC 700221) and Enterococcus faecalis (ATCC 29212), using the wagon-wheel co-culture technique as described above (Figure 2B). Frozen glycerol stock cultures of the Arctic isolates and of the tester pathogens were streaked on LB plates. The pathogen tester strains were incubated at 37°C for 18 h whereas Arctic isolates were incubated at room temperature for 48 h. Once sufficient growth appeared on plates, liquid cultures of the Arctic isolates and the pathogenic tester strains were made using LB media. Liquid cultures of the Arctic isolates were incubated with agitation at 250 rpm for 48 h at room temperature whereas pathogenic tester strains were incubated with agitation at 250 rpm for 24 h at 37°C. Loopfuls of the pathogenic strains in liquid culture were streaked in a circular line on a LB plate, while the Arctic isolates were streaked outward starting from the middle of the plate (Figure 2B). Triplicates of these co-culture plates were incubated at room temperature, and observed after 24, 48, and 72 h of incubation. Regions of contact between the Arctic isolate and pathogenic tester strain in which the tester strain did not produce visible growth were recorded as inhibition.

1https://nucleobases.com/
TABLE 1 | Arctic samples collected from Expedition Fiord, Axel Heiberg Island, Nunavut, used as source material for bioprospecting of antibiotic-producing strains.

| Sample type       | Source location                        | Geographic coordinates | Habitat                                                                 |
|-------------------|----------------------------------------|------------------------|-------------------------------------------------------------------------|
| Active Layer Permafrost | MARS station Expedition Fiord          | (79.412872, – 90.740343) | Trough soil from polygonal tundra terrain Surface soil from polygonal tundra terrain Arid soil Active layer tundra permafrost |
| Sediments         | Gypsum Hill, Expedition Fiord          | (79.403906, – 90.732321) | Hummock soil                                                            |
|                   | Junction Diapir (Lost Hammer)          | (79.076755, –90.195299) | Perennial hypersaline (22–23% salt) spring outflow channel sediment     |
|                   | Color Lake, Expedition Fiord           | (79.416300, – 90.764081) | Acidic (pH 3.6) freshwater lake sediment covering microbial mat         |
| Lithic Communities | Gypsum Hill, Expedition Fiord          | (79.412151, – 90.740644) | Gypsum cryptoendolith                                                   |
|                   | Junction Diapir (Lost Hammer)          | (79.407655, –90.195299) | Unidentified rock cryptoendolith                                        |

Assessing Growth of Arctic Isolates That Passed the ARP at Various Temperatures

Liquid TSB cultures of Arctic isolates were incubated with agitation at 250 rpm for 48 h at room temperature and then streaked on TSA plates. Inoculated plates were then incubated at 37, 25, 10, 5, 0, –5, and –10°C. TSA media intended for sub-zero incubation was amended with 3% v/v glycerol to avoid complete freezing of the media. Growth was visually assessed after 48 h of incubation at 37 and 25°C. The remaining incubations were assessed for growth after 20 days.

Screening Arctic Isolates That Passed the ARP Against Foodborne Pathogens

In addition to screening against clinical pathogens, all Arctic isolates that passed the dereplication assay were screened against foodborne pathogens using an overlay co-culture assay (Figure 2C). Liquid TSB cultures of Arctic isolates were incubated with agitation at 250 rpm for 2 days at room temperature and then streaked in a line in the center of the TSA plates. The TSA plates were then left to incubate at room temperature for 7 days. Following incubation, each Arctic isolate was overlaid with 7 ml of molten agar media inoculated with 100 µl of overnight liquid cultures of S. aureus WT, Listeria monocytogenes HPB# 1870 serotype 1/2c, Salmonella enterica serovar Heidelberg, and E. coli 0157:H7. To assess whether any of the secreted secondary metabolites produced by the Arctic isolates retained inhibitory activity at human body and standard refrigeration temperatures, the overlay plates were incubated at 37 and 5°C, respectively. Zones of inhibition were observed after 24 h of incubation for plates incubated at 37°C and after 20 days for those incubated at 5°C. This assay inherently relies on the diffusion of secreted molecules within the cultivation media’s semisolid agar matrix. Specifically, in order to observe zones of clearance, diffusible biomolecules are required to reach the top agar layer to inhibit the tester strains. This co-culture assay was conducted in triplicate and an established antibiotic-producing strain, Paenibacillus terrae NRRL B-30644, was used as a positive control.
control. This environmental strain has been previously reported to produce zones of inhibition in co-culture assays against foodborne pathogens (van Belkum et al., 2015). The zones of inhibition produced by P. terrae NRRL B-30644 served as a visual reference for positive inhibitory activity for all the co-culture assays conducted in this study (Figure 2C).

DNA Sequencing, Genome Assembly, and Analyses of Isolates Passing the ARP

Bacterial isolates were inoculated from single isolated colonies into R2A broth and grown at room temperature for periods ranging from 12 to 72 h. The genomic DNA was extracted using the E-Z 96 Tissue DNA Kit (Omega Bio-Tek, Norcross, GA, United States). Between 250 and 700 ng of DNA were fragmented via sonication using a Covaris M220 (Covaris, Woburn, MA, United States) for 40 s at 18–22°C. The peak power was set at 50.0, duty factor at 20.0 and the number of bursts at 200. The libraries were prepared using the NEBNext Ultra II DNA library prep kit for Illumina (New England Biolabs, Ipswich, MA, United States) following the manufacturer’s instructions. The libraries were barcoded with TruSeq HT adapters (Illumina, San Diego, CA, United States) and sequenced using an Illumina MiSeq 300 bp paired-end run at the Plateforme d’Analyses Génomiques at the Institut de Biologie Intégrative et des Systèmes (Université Laval, Québec, Canada). The raw reads were assembled using the A5 pipeline (Tritt et al., 2012). Assemblies were validated using the metagenomic identification software Centrifuge and contig uniformity was verified to confirm that each assembly originated from the same source DNA and from not contaminants (Kim et al., 2016). To taxonomically identify the isolates that inhibited the ARP, their assembled genomes were first annotated using the Rapid Annotation using Subsystem Technology (RAST) version 2.0 using standard parameters (Aziz et al., 2008; Overbeek et al., 2013; Brettin et al., 2015). Following annotation, full 16S rRNA gene(s) were identified within each genome and subsequently used as a query sequence in the EzBioCloud database for corroborating taxonomical identification (Yoon et al., 2017). To predict the secondary metabolite BGCs within the genomes of the eight isolates of interest, all genomes were mined using the antiSMASH database v.4 using default search parameter settings (Medema et al., 2011; Blin et al., 2017). The BGCs of the isolates showing the broadest activity spectra were used as query sequence in a blastn alignment against genomes of type strains of the same species: Pseudomonas proskeii LMG 26867 (genome accession GCA_900105155.1), and P. terrae NRRL B-30644 (accession GCA_000943545.1). The assembled genomes of these two promising isolates were deposited at GenBank under the BioSample accessions (SAMN12211638 and SAMN12211639).

Organic Extraction Using Liquid Culture Supernatants From Two Promising Isolates

To confirm whether the antagonistic activities of promising isolates were caused by secreted secondary metabolites of bacterial origin, organic extracts using liquid culture supernatants were prepared. Isolates were incubated overnight in TSB media at room temperature with agitation at 250 rpm. Following overnight incubation, 14 mL of the cultures were mixed with 7.5 mL of ethyl acetate in a 50 mL Falcon tube (giving a final volume ratio of 2:1 culture supernatant to ethyl acetate). Solutions were vortexed on the highest setting until solutions were homogenized and then centrifuged at 7830 rpm for 15 min at room temperature. Following centrifugation, the organic layers were removed from both solutions and were collected in separate pre-weighted 7.5 mL borosilicate glass culture tubes using a Pasteur pipette. The ethyl acetate was then left to evaporate for 20 min by direct air filtered with a 0.3 µm HEPA filter (Whatman #0974479). After the solvent fully evaporated, both extracts were resuspended in 200 µL of methanol. To assess whether the crude organic extracts retained antibacterial activity, 30 µL of the extracts were spotted on agar plates. Once the methanol fully evaporated from the agar, 7 mL of molten agar containing the tester strains (E. coli ATCC 11775 and E. coli ΔbamΔtolC BW25113) were poured over the dried extract spots. Control spots consisting only of methanol were plated to confirm that the observed zones of clearance did not arise from the solvent used to resuspend the extract. The plates were then incubated at room temperature for 24 h before being observed for zones of clearance.

RESULTS

Antibiotic Activity of Arctic Isolates Against ESKAPE Pathogen Relatives

Twelve environmental samples were collected in the regions of Expedition Fiord, Gypsum Hill, Lost Hammer, Color Lake and White Glacier on Axel Heiberg Island in the Canadian high Arctic. The sampled habitats included active layer permafrost, and lithic communities. Active layer permafrost samples included trough soil from polygonal tundra terrain, surface soil from polygonal tundra terrain, arid soil, and hummock soil. Sediment samples included perennial hypersaline spring outflow channel sediment, acidic freshwater lake sediment, acidic freshwater lake sediment covered with microbial mats, perennial saline spring sediment, and sediment from glacial terminus moraines. Lithic communities included gypsum cryptoendoliths and unknown rock cryptoendoliths (Table 1). All of these samples were distributed to the undergraduate students for traditional plate cultivation, and 3120 distinct colonies were subcultured and further tested. After co-culture screening, 54 isolates (1.7%) were identified as having antibacterial activity against at least one ESKAPE pathogen relative. Of these, three isolates originated from acidic freshwater lake sediment covered with microbial mat, four from a gypsum cryptoendolith, seven from Gypsum Hill hummock active layer permafrost, three from Gypsum Hill perennial saline spring sediment, one from a cryptoendolith collected at Lost Hammer, 25 from active layer tundra permafrost, seven from arid active layer permafrost, two from polygonal terrain surface soil, one from polygonal terrain trough soil, and one from glacial terminus moraine sediment (Table 2). The genera represented
## TABLE 2 | Antibiotic activity of bulk soil isolates against ESKAPE pathogen relatives.

| Source location                      | Habitat                          | Isolate name               | Closest matching taxon               | % identity | % coverage of 16S gene | S. epidermidis | E. raffinosus | E. coli | P. putida | A. baylyi | E. aerogenes |
|--------------------------------------|----------------------------------|----------------------------|-------------------------------------|------------|------------------------|----------------|---------------|---------|-----------|-----------|--------------|
| Color Lake, Acidic freshwater lake sediment | Covered with microbial mat     | CLMS.5.EMGM.4              | Janthinobacterium lividum            | 99.87      | 54.6                   |                |               |         |           |           |              |
| Expedition Fiord                     |                                  | CLMS.5.EMGM.9              | Pseudomonas yannanorum              | 100        | 54.9                   |                |               |         |           |           |              |
|                                     |                                  | CLMS.6.VMCS.4              | Janthinobacterium lividum            | 99.87      | 29.6                   |                |               |         |           |           |              |
| Gypsum Hill, Expedition Fiord        | Gypsum cryptoendolith            | GHCE.C1.AWCA.27            | Streptomyces avidinii               | 100        | 48.2                   |                |               |         |           |           |              |
|                                     |                                  | GHCE.C1.AWCA.31            | Mycobacterium mubieriensis          | 99.75      | 56.3                   |                |               |         |           |           |              |
| Hummock soil                         |                                  | GHCE.5.JVZL.12             | Pseudomonas fulva                   | 100        | 100                    |                |               |         |           |           |              |
|                                     |                                  | GHCE.5.JVZL.15             | Streptomyces avidinii               | 100        | 46.4                   |                |               |         |           |           |              |
| Gypsum Hill, Expedition Fiord        | Gypsum cryptoendolith            | GHHS.3.LBZX.4              | Flavobacterium paraniterrae         | 99         | 100                    |                |               |         |           |           |              |
|                                     |                                  | GHHS.3.LBZX.18             | Janthinobacterium svalbardensis     | 100        | 59.5                   |                |               |         |           |           |              |
|                                     |                                  | GHHS.LB.ZLB.24             | Pseudomonas heilmanticiensis        | 99.75      | 54.8                   |                |               |         |           |           |              |
|                                     |                                  | GHHS.LB.ZLB.15             | Pseudomonas heilmanticiensis        | 100        | 54                     |                |               |         |           |           |              |
|                                     |                                  | GHHS.LB.ZLB.15             | Pseudomonas arsenicoxydans          | 100        | 54.8                   |                |               |         |           |           |              |
|                                     |                                  | GHHS.LB.ZLB.9              | Pseudomonas arsenicoxydans          | 100        | 46.2                   |                |               |         |           |           |              |
|                                     |                                  | GHHS.13.PTLY.2             | Pseudomonas arsenicoxydans          | 100        | 53.9                   |                |               |         |           |           |              |
|                                     |                                  | GHS.C1.PZCG.3              | Bacillus nakamurai                  | 100        | 45.9                   |                |               |         |           |           |              |
|                                     |                                  | GHS.C1.PZCG.16             | Micrococcus aloeverae               | 99.85      | 46.8                   |                |               |         |           |           |              |
|                                     |                                  | GHS.8.NWYW.5               | Paenibacillus terrae                | 99.23      | 100                    |                |               |         |           |           |              |
| Junction Diapir, (Lost Hammer)       | Unknown rock cryptoendolith     | LCE.5.TZJR.21              | Pseudomonas lurida                  | 99.87      | 54.7                   |                |               |         |           |           |              |
| MARS station                         | Active layer                    | MAL.2.HSSH.5               | Pseudomonas kilonensis              | 99.86      | 48.5                   |                |               |         |           |           |              |
| Expedition Fiord, tundra permafrost  |                                  | MAL.4.ABES.12              | Pseudomonas arsenicoxydans          | 99.86      | 49.6                   |                |               |         |           |           |              |
|                                     |                                  | MAL.4.ABES.21              | Pseudomonas frederikobergenensis    | 100        | 100                    |                |               |         |           |           |              |
|                                     |                                  | MAL.11.AHOHQX.12           | Pseudomonas arsenicoxydans          | 100        | 100                    |                |               |         |           |           |              |
|                                     |                                  | MAL.10.WYTK.25             | Pseudomonas extrematrauls            | 99.73      | 100                    |                |               |         |           |           |              |
|                                     |                                  | C2C25                      | Curtobacterium paratum              | 99.54      | 100                    |                |               |         |           |           |              |
|                                     |                                  | C5C25                      | Pseudomonas migulae                 | 99.6        | 100                    |                |               |         |           |           |              |
|                                     |                                  | HTAG2                      | Pseudomonas jessenii                | 99.34      | 100                    |                |               |         |           |           |              |
|                                     |                                  | Q6A2                       | Nocardia coelia                     | 99.62      | 100                    |                |               |         |           |           |              |
|                                     |                                  | Q6A4                       | Streptomyces netropsis              | 100        | 100                    |                |               |         |           |           |              |
|                                     |                                  | C7F1                       | Nocardia coelia                     | 99.61      | 100                    |                |               |         |           |           |              |
|                                     |                                  | C4F16                      | Arthrobacter cryzae                 | 99.46      | 100                    |                |               |         |           |           |              |

(Continued)
| Source location | Habitat | Isolate name | Closest matching taxon | % identity | % coverage of 16S gene | S. epidermidis | E. raffinosus | E. coli | P. putida | A. baylyi | E. aerogenes |
|-----------------|---------|--------------|------------------------|------------|------------------------|----------------|---------------|---------|-----------|-----------|-------------|
| Arid soil       |         | C6D6         | Nocardia globerula     | 99.34      | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | C6D9         | Pseudoarthrobacter phenanthrenivorans | 99.09      | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | C7B19        | Nocardia coeliaca      | 99.61      | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | C7B21        | Bacillus mycoide       | 99.69      | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | C7D7         | Paenibacillus xylanexedens | 100        | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | C8B11        | Rahnella inustata      | 98.59      | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | C8C11.16     | Bacillus subtilis      | 99.74      | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | C10F22       | Nocardia coeliaca      | 99.59      | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | C10F26       | Pseudomonas fluorescens | 99.28      | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | C10G6        | Nocardia globerula     | 99.34      | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | C11E10       | Bacillus subtilis      | 100        | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | C11E23       | Bacillus tequilensis   | 99.87      | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | MAL.11.SPBE.1 | Pseudomonas arsenoxydans | 99.75      | 55.9                   | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | AALPS.3.MFAL.10 | Pseudomonas lutea       | 100        | 36                     | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | AALPS.2.KEKID.20 | Pseudomonas mandeli     | 99.73      | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | AALPS.4.MSMB.5 | Pseudomonas mandeli     | 99.66      | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | AALPS.10.JKNJ.7 | Pseudomonas proteki      | 100        | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | AALPS.10.EMMH.23 | Pseudomonas yamnamorum | 98.68      | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | AALPS.10.MNAAK.13 | Pseudomonas proteki      | 99.93      | 100                    | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | AALPS.13.YAYA.22 | Pseudomonas proteki      | 100        | 21                     | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | PSALP.2.BBGP.18 | Pseudomonas luctia      | 99.84      | 42.6                   | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | PSALP.2.JGGR.13 | Pseudomonas kilonensis  | 99.87      | 53.8                   | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | PWALP.2.KADK.9 | Pseudomonas fluorescens | 100        | 46.9                   | Red            | Black         | Black   | Black     | Black     | Black       |
|                 |         | GS.C1.SPSB.3  | Siccibacter turicensis | 100        | 53.9                   | Red            | Black         | Black   | Black     | Black     | Black       |

Red boxes: inhibitory activity. Black boxes: no inhibitory activity.
by these 54 isolates were *Pseudomonas* (27 isolates), *Bacillus* (5), *Nocardia* (6), *Janthinobacterium* (3), *Streptomyces* (3), *Paenibacillus* (2), *Microcytoca* (1), *Flavobacterium* (1), *Micrococcus* (1), *Curtobacterium* (1), *Arthrobacter* (1), *Pseudoarthrobacter* (1), *Rahnella* (1), and *Siccibacter* (1).

Microbial cultivation using the cryo-iPlate incubated in active layer permafrost soil within the vicinity of the MARS lead to the isolation of ~300 morphologically distinct colonies. A total of 16 isolates (~5%) exhibited antibacterial activity against at least one ESKAPE pathogen relative. All cryo-iPlate strains with antibacterial activity only displayed zones of inhibition against *P. putida* except for Pedobacter isolate B7.1 that inhibited *S. epidermidis*, and *Flavobacterium* strain C9.2 that inhibited the growth of *E. coli* and *P. putida* (Table 3). Genera represented by these 16 isolates were *Pseudomonas* (4 isolates), *Pedobacter* (3), *Flavobacterium* (3), *Janthinobacterium* (2), *Agreia* (1), *Pararhizobium* (1), *Sphingomonas* (1), and *Stenotrophomonas* (1) (Table 3). The genera isolated by both the classical soil plating approach and the cryo-iPlate were *Pseudomonas*, *Flavobacterium*, and *Janthinobacterium*. Among both bulk plated and cryo-iPlate isolates, *Pseudomonas* represented the genus with the highest proportion of total isolated strains (50% of total bulk plated isolates and 25% of total cryo-iPlate isolates).

**Antibacterial Activity of Arctic Isolates That Passed the ARP Against Clinical Pathogens**

Eight (8) out of the total seventy (70) antibiotic-producing isolates (11%) were found to inhibit the growth of all strains comprising the ARP. These strains were prioritized for further investigation. To assess whether these isolates were capable of inhibiting the growth of clinically significant pathogens, the isolates were screened against ESKAPE organisms *P. aeruginosa*, MRSA, *A. baumanii*, MSSA, *E. cloacae*, *K. pneumoniae*, *E. faecium*, and *E. faecalis*. *Pseudomonas* sp. AALPS.10.MNAAK.13 was observed to have the broadest antibacterial activity spectrum. It inhibited the growth of *E. coli* and *P. putida* (Table 3). The isolate featuring the least number of BGCs within its genome *Pseudomonas* sp. AALPS.10.MNAAK.13 was observed to inhibit MRSA and MSSA. *Pseudomonas* sp. MAL.10.WYTK.25 was observed to inhibit the growth of *S. enterica* at 37°C after 24 h. *Bacillus* sp. C11E23 inhibited *L. monocytogenes* at 37 and 5°C (Table 6). The zones of inhibition produced by these Arctic isolates were consistent with the known antibiotic-producing strain *P. terrae* NRRL B-30644 which displayed inhibitory activity against all foodborne pathogens used in this assay.

**Genomic Analysis of Bacterial Isolates Capable of Inhibiting the Entire ARP**

After the Illumina MiSeq 300 bp paired-end run, the range of number of raw reads was 665502–2929247 and the fragment size range was 400–2000 bp (Supplementary Table S4 and Supplementary Figure S1). The genomes of the eight prioritized isolates were then mined using the antiSMASH database to identify secondary metabolite gene clusters that they encode (Table 4). These genomes contained ≥6 putative BGCs that were homologous to NRP, PK, bacteriocin/ribosomally synthesized and post-translationally modified peptide (RiPP), and trans-polypeptide synthetase (trans-PKS). All clusters labeled as “other” corresponded to either arylpolyene, terpene, beta lactone, siderophore, N-acetylglutaminylglutamine (NAGGN) amide or phosphonate clusters (not shown in table). The genome of *Paenibacillus* sp. GHS.8.NWYW.5 featured the greatest number of BGCs compared to all other isolates with 23 secondary metabolite clusters. These clusters included 17 NRP clusters, three bacteriocin/RiPP clusters, one trans-PKS cluster, and two other clusters (one siderophore and one phosphonate cluster). The isolate featuring the least number of BGCs within its genome was *Flavobacterium* sp. GHS.3.LBZX.4 with a total of six secondary metabolite clusters. These included one type-3 PK, one NRP and four other clusters (one arylpolyene cluster, two terpene clusters, and one beta lactone cluster). *Pseudomonas* sp. AALPS.10.MNAAK.13 and *Paenibacillus* sp. GHS.8.NWYW.5 represent the two isolates that displayed the broadest spectra of antibacterial activities against foodborne and clinical pathogens. Eight BGCs were identified within the genome of *Pseudomonas* sp. AALPS.10.MNAAK.13 using antiSMASH (Table 7). After conducting a blastn alignment between the isolate’s clusters with the *Pseudomonas proszekii* LMG 26867 type strain genome, none of the detected clusters displayed low homology within

**Growth of Arctic Isolates That Passed the ARP at Various Temperatures**

After screening against clinically significant pathogens, we assessed whether the eight prioritized isolates were capable of growing at various temperatures (37, 25, 10, 5, 0, and –5°C). All eight isolates were capable of growth at 5°C. Only two isolates (*Paenibacillus* sp. GHS.8.NWYW.5 and *Pseudomonas* sp. GHS.5.JVZL.12) were capable of growing at 37°C after 48 h of incubation. All isolates except *Pseudomonas* sp. GHS.5.JVZL.12 grew at 0°C after 20 days of incubation. With the exception of *Flavobacterium* sp. GHS.3.LBZX.4 and *Pseudomonas* sp. GHCE.5.JVZL.12, all other Arctic isolates that passed the ARP were capable of growing at –5°C after 20 days of incubation (Supplementary Table S3).

**Antibacterial Activity of Prioritized Isolates Against Foodborne Pathogens**

The eight prioritized isolates were tested for antibacterial activity against four foodborne pathogens (*S. aureus*, *L. monocytogenes*, *S. enterica* and *E. coli* O157:H7 at two different incubation temperatures (37 and 5°C). *Paenibacillus* sp. GHS.8.NWYW.5 was observed to inhibit the growth of *S. aureus*, *L. monocytogenes*, *S. enterica*, and *E. coli* O157:H7 at 37 and 5°C. *Pseudomonas* sp. AALPS.10.MNAAK.13 was observed to inhibit *S. aureus* at 37°C after 24 h of incubation. *Pseudomonas* sp. MAL.10.WYTK.25 was observed to inhibit the growth of *S. enterica* at 37°C after 24 h. *Bacillus* sp. C11E23 inhibited *L. monocytogenes* at 37 and 5°C (Table 6). The zones of inhibition produced by these Arctic isolates were consistent with the known antibiotic-producing strain *P. terrae* NRRL B-30644 which displayed inhibitory activity against all foodborne pathogens used in this assay.

---

Marcolenas et al.

**Arctic Bacteria Displaying Antibacterial Activity**

Frontiers in Microbiology | www.frontiersin.org August 2019 | Volume 10 | Article 1836
TABLE 3 | Antibiotic activity of cryo-iPlate isolates against ESKAPE pathogen relatives.

| Isolate name | Closest match       | % identity | S. epidermidis | E. raffinosus | E. coli | P. putida | A. baylyi | E. aerogenes |
|--------------|---------------------|------------|----------------|---------------|---------|-----------|----------|-------------|
| A4.3Y        | Janthinobacterium lividum | 99.31      |                |               |         |           |          |             |
| B1.1W        | Pseudomonas trivialis | 100        |                |               |         |           |          |             |
| B4.6         | Pseudomonas migulae   | 100        |                |               |         |           |          |             |
| B7.1         | Pedobacter humicola   | 99.01      |                |               |         |           |          |             |
| C2.3         | Pedobacter alluvionis | 99.09      |                |               |         |           |          |             |
| C6.2         | Pseudomonas koreensis | 100        |                |               |         |           |          |             |
| C7.3         | Agrewa pratensis      | 100        |                |               |         |           |          |             |
| D4.1         | Pseudomonas arsenicoyxans | 100        |                |               |         |           |          |             |
| G2.2         | Flavobacterium oncorhynchi | 100        |                |               |         |           |          |             |
| F9.3         | Pedobacter terrae     | 95.59      |                |               |         |           |          |             |
| D1.3         | Janthinobacterium lividum | 99.25      |                |               |         |           |          |             |
| C12.2A       | Stenotrophomonas rhizophila | 99.49      |                |               |         |           |          |             |
| C12.1B       | Flavobacterium frigidimar | 99.2       |                |               |         |           |          |             |
| C11.2        | Pararhizobium herbae  | 100        |                |               |         |           |          |             |
| C11.3        | Sphingomonas aerolata  | 99.68      |                |               |         |           |          |             |
| C9.2         | Flavobacterium hydatis  | 100        |                |               |         |           |          |             |

Red boxes: positive inhibitory activity. Black boxes: negative inhibitory activity.

TABLE 4 | Identification of secondary metabolite biosynthetic gene clusters within genomes of isolates inhibiting the ARP.

| Isolate Identification | Genome size (Mb) | %16S gene ID | AntiSMASH (total clusters) | NRP | PK | Bacterio/ RPP | Trans PKS | Other |
|------------------------|------------------|--------------|-----------------------------|-----|----|--------------|-----------|-------|
| GHHS.3.LBZX.4          | 6.1              | 87.54        | 6                           | 1   | 1  | 0            | 0         | 4     |
| GHS.8.NWYW.5           | 5.7              | 99.23        | 23                          | 17  | 0  | 3            | 1         | 2     |
| MAL.10.WYTK.25         | 6.8              | 99.73        | 9                           | 4   | 0  | 2            | 0         | 3     |
| GHCE.5.JVZL.12         | 5                | 100          | 11                          | 9   | 0  | 0            | 0         | 0     |
| AALPS.4.MSMB.5         | 6.3              | 99.66        | 10                          | 3   | 0  | 3            | 1         | 3     |
| AALPS.10.MNAAK.13      | 6.1              | 99.93        | 8                           | 2   | 0  | 1            | 0         | 5     |
| MAL.4.ABES.21          | 7.1              | 99.86        | 7                           | 3   | 0  | 1            | 0         | 3     |
| C11E23                 | 4.3              | 100          | 12                          | 4   | 1  | 3            | 1         | 3     |

1 Number of non-ribosomal peptide gene clusters identified using AntiSMASH. 2 Number of polyketide gene clusters identified using AntiSMASH. 3 Number of bacteriocin and ribosomally synthesized and post-translationally modified peptides (RiPP) identified using AntiSMASH. 4 Number of trans-polyketide gene clusters identified using AntiSMASH.

DISCUSSION

Arctic Bacteria Demonstrate Antibiotic Activity Against ESKAPE Pathogen Relatives

Bacteria capable of inhibiting ESKAPE pathogen relatives were isolated from all sampled Arctic environments, with the type strain genome. The genome of the Paenibacillus sp. GHS.8.NWYW.5 featured 23 BGCs (Table 7). The clusters with low homology (<50% coverage, <30% identity, and e-values > 0) to the type strain genome of P. terrae NRRL B-30644 included: one NRP cluster displayed 11% coverage and 98% identity, one NRP cluster matching to pelgipeptin displayed 45% coverage and 97% identity, one NRP cluster displayed 41% coverage and 75% identity, and two unknown NRP clusters that did not have any significant homology with the type strain genome.

Organic Extraction Using Liquid Culture Supernatants

Organic extracts using liquid culture supernatants from isolates Paenibacillus sp. GHS.8.NWYW.5, Pseudomonas sp. AALPS.10.MNAAK.13, Pseudomonas sp. AALPS.10.EMMH.23, Pseudomonas sp. AALPS.10.KJN.7, Pseudomonas sp. AALPS.4.MSMB.5, Pseudomonas sp. GHCE.5.JVZL.12, Pseudomonas sp. MAL.10.WYTK.25 (same isolate as 7.EKIG.16 in Figure 3) were prepared using ethyl acetate. The crude organic extracts were then tested for retained antibacterial activity using a plate-based spot assay against the parental strains of the ARP (E. coli ΔbamΔtolC BW25113 and E. coli BW25113). After 24 h of incubation at room temperature, the extracts of Pseudomonas sp. AALPS.10.MNAAK.13, Pseudomonas sp. AALPS.10.EMMH.23 and Paenibacillus sp. GHS.8.NWYW.5 exhibited zones of inhibition against E. coli ΔbamΔtolC BW25113 (Figures 3A,D). The extract of Pseudomonas sp. AALPS.10.EMMH.23, yielded a zone of inhibition against E. coli BW25113 (Figure 3B).
exception of perennial hypersaline spring sediment sample from Lost Hammer. A total of 70 antibiotic producing isolates were identified, with 54 coming from a classical bulk soil plating approach, and 16 from cryo-iPlate cultivation. More isolates were obtained from the bulk plating approach aided by the greater throughput of approximately 130 undergraduate students processing samples in parallel, while the cryo-iPlate samples were processed by only two graduate students. Additionally, the volume of Arctic samples used for classical plating to isolate microorganisms was ~60 times greater than that used to inoculate the cryo-iPlate. None of the isolates with antibacterial activity were obtained from perennial hypersaline spring sediment from Lost Hammer, which may be because the salt content of the cultivation media was not adjusted to select for halophilic strains. It is known that the perennial hypersaline spring sediment at Lost Hammer hosts an active microbial community including members of the *Loktanella*, *Gillisia*, *Halomonas* and *Marinobacter* genera (Niederberger et al., 2010), and lack of isolates therefore cannot be attributed to lack of viable bacteria in the source material.

The sample type that yielded the greatest number of isolates with antibiotic activity was active layer soils overlaying permafrost, which consists of a low carbon mineral cryosol. It is ~60 cm deep during the Arctic summer and completely freezes during winter and spring (Doran, 1993; Lau et al., 2015; Goordial et al., 2017). Previously cultured phylotypes from this habitat predominantly included Actinobacteria (Niederberger et al., 2010), and indeed 26% of isolates identified by the bulk soil plating approach belonged to the Actinobacteria. This phylum includes the genus *Streptomyces* which are known to be prolific producers of antibiotics (Kiesser et al., 2000; Manivasagan et al., 2014). A previous study using functional metagenomics showed that antibiotic resistance genes are present in similar permafrost soils at nearby Eureka, Ellesmere Island (Perron et al., 2015). The presence of antibiotics will create selective pressure for the development of antibiotic resistance. The presence of both antibiotic activity and antibiotic resistance therefore suggests interactions between these functions in the microbial permafrost community.

All cryo-iPlate strains were derived from active layer permafrost soil, because this was the only sample type in which the cryo-iPlate was incubated. The cryo-iPlate yielded genera (*Pararhizobium*, *Sphingomonas*, *Stenotrophomonas*, *Agreia*, *Pedobacter*) that were not observed in the strains isolated by the classical method from the same environment. In the initial implementation of the cryo-iPlate prototype, many of the same genera were isolated, including a putatively novel *Pedobacter* strain (Goordial et al., 2017). Similarly, *Pedobacter* strain F9.3 derived from the cryo-iPlate in this study was found to have 95.6% 16S rRNA gene sequence identity to its closest match *Pedobacter terrae* (*Table 3*). While none of the cryo-iPlate derived strains inhibited the entire ARP, they were able to inhibit the growth of both Gram-positive and Gram-negative relatives of the ESKAPE pathogens. Given that these strains were isolated from cryohabitats, their antibacterial activity has potential

---

**TABLE 5** Screening Arctic isolates that inhibited the ARP against clinical pathogens.

| Isolate name | Closest matching species | Closest matching strain |
|--------------|--------------------------|------------------------|
| GHHS.3.LBZX.4 | *Flavobacterium panaciterrae* | DCY69(T) |
| GHS.8.NWYW.5 | *Paenibacillus terrae* | AM141(T) |
| AALPS.10.MNAAK.13 | *Pseudomonas prosekii* | LMG 26867 |
| MAL.10.WYTK.25 | *Pseudomonas extremaustralis* | 14-3(T) |
| GHCE.5.JVZL.12 | *Pseudomonas fluorescens* | DSM 50090(T) |
| AALPS.4.MSMB.5 | *Pseudomonas mandelii* | NBRC 103147(T) |
| MAL.4.ABES.21 | *Pseudomonas frederikbergensis* | JAJ28(T) |
| C11E23 | *Bacillus tequilensis* | KCTC 13622(T) |

(+ Positive inhibitory activity.)
### TABLE 6 | Screening Arctic isolates that inhibited the ARP against foodborne pathogens.

| Isolate name     | Closest matching species               | Closest matching strain | Staphylococcus aureus | Listeria monocytogenes | Salmonella enterica | Escherichia coli O157:H7 |
|------------------|---------------------------------------|-------------------------|-----------------------|------------------------|---------------------|--------------------------|
|                  |                                       |                         | 37°C | 5°C | 37°C | 5°C | 37°C | 5°C | 37°C | 5°C |
| GHHS.3.LBZX.4    | Flavobacterium panaciterrae           | DCY69(T)                | +    | +   | +    | +   | +    | +   | +    | +   |
| GHS.8.NWYW.5     | Paenibacillus terrae                 | AM141(T)                | +    | +   | +    | +   | +    | +   | +    | +   |
| AALPS.10.MNAAK.13| Pseudomonas proseki                 | LMG 26867               | +    | +   | +    | +   | +    | +   | +    | +   |
| MAL.10.WYTK.25   | Pseudomonas extremaustralis          | 14-3(T)                 | +    | +   | +    | +   | +    | +   | +    | +   |
| GHCE.5.JVZL.12   | Pseudomonas fluorescens             | DSM 50090(T)            | +    | +   | +    | +   | +    | +   | +    | +   |
| AALPS.4.MSMB.5   | Pseudomonas mandelli                | NBRC 103147(T)          | +    | +   | +    | +   | +    | +   | +    | +   |
| MAL.4.ABES.21    | Pseudomonas frederikbergensis       | JAJ28(T)                | +    | +   | +    | +   | +    | +   | +    | +   |
| C11E23           | Bacillus tequilensis                | KCTC 13622(T)           | +    | +   | +    | +   | +    | +   | +    | +   |

(+) Positive inhibitory activity.

### TABLE 7 | Comparing secondary metabolite gene clusters identified within genomes of promising isolates with type strains of the same species.

| Isolate^a | Type strain genome^b | BGC category^c | Closest matching known BGC^d | Coverage (%)^e | ID (%)^f | e-value^g |
|-----------|----------------------|----------------|-----------------------------|----------------|----------|-----------|
| AALPS.10.MNAAK.13 (Pseudomonas proseki) | Pseudomonas proseki LMG 26867 | NRP | pyoverdine | 95 | 97.99 | 0 |
|           |                      | betalactone  | fengycin                     | 100            | 98.3     | 0 |
|           |                      | terpene     | –                           | 66             | 99.03    | 0 |
|           |                      | arylophone  | APE v                        | 95             | 98.63    | 0 |
|           |                      | hserlactone | –                           | 99             | 98.87    | 0 |
|           |                      | bacteriocin | bacillomycin                 | 100            | 98.22    | 0 |
|           |                      | NAGGN       | –                           | 100            | 98.63    | 0 |
|           |                      | NRP         | pyoverdine                   | 99             | 98.40    | 0 |
|           |                      | siderophore | staphylbactin                | 88             | 95       | 0 |
|           |                      | lanthipeptide | paenicidin B             | 100            | 96       | 0 |
|           |                      | phosphonate | –                           | 58             | 95       | 0 |
|           |                      | lassoipeptide | –                        | 100            | 95       | 0 |
|           |                      | NRP         | –                           | 54             | 93       | 0 |
|           |                      | NRP         | calicheamicin                | 89             | 95       | 0 |
|           |                      | NRP         | trans-ATPKS                  | 71             | 93       | 0 |
|           |                      | NRP-betalactone | –                    | 60             | 91       | 0 |
|           |                      | NRP         | –                           | 58             | 94       | 0 |
|           |                      | NRP         | –                           | 11             | 98       | 0 |
|           |                      | NRP         | –                           | 93             | 92       | 0 |
|           |                      | NRP         | fusicaricin                  | 99             | 93       | 0 |
|           |                      | NRP         | –                           | 37             | 65       | 0 |
|           |                      | NRP         | pelgipeptin                  | 45             | 97       | 0 |
|           |                      | NRP         | –                           | NA             | NA       | NA |
|           |                      | NRP         | –                           | 41             | 75       | 0 |
|           |                      | NRP         | –                           | NA             | NA       | NA |
|           |                      | NRP         | polymyxin                   | 62             | 69       | 0 |
|           |                      | NRP         | tridecaptin                 | 44             | 69       | 7e-141 |
|           |                      | NRP         | –                           | 55             | 69       | 0 |
|           |                      | NRP         | –                           | 46             | 73       | 8e-36 |
|           |                      | NRP         | –                           | 96             | 73       | 0 |
|           |                      | NRP         | –                           | 65             | 70       | 5e-38 |
|           |                      | NRP         | –                           | 46             | 67       | 1e-33 |
|           |                      | NRP         | paenibacterin               | 38             | 74       | 1e-35 |
|           |                      | NRP         | –                           | 61             | 69       | 3e-38 |

^a Prioritized isolates displaying widest spectra of antagonistic activity against foodborne and ESKAPE pathogens. ^b Corresponding type strain genome of isolates’ species. ^c Category of secondary metabolite BGCs within genomes of isolates identified using the antiSMASH database. ^d Closest match to known secondary metabolite clusters within isolates’ genomes. ^e Percent coverage of Arctic isolates’ BGCs within reference genomes. ^f Percent identity of Arctic isolates’ BGCs within reference genomes. ^g e-value of Arctic isolates’ BGCs within reference genomes.
applications in food safety, where inhibitory activity is required at refrigeration temperatures.

Eight Arctic Bacterial Isolates Inhibited All ARP Strains

Here we have identified eight isolates able to inhibit the ARP which corresponded to either Firmicutes, Bacteroidetes or \( \gamma \)-Proteobacteria. It is worth noting that the dereplication method employed in this study is not a comprehensive approach in identifying isolates expressing novel antibiotic compounds. For example, if a given antibiotic-producing isolate expresses more than one antimicrobial secondary metabolite, it would be capable of inhibiting the growth of all strains comprising the ARP regardless of whether the mechanisms of action of its secondary metabolites are novel. Given this inherent limitation of the ARP, the benefit of using this platform is an initial quick and cost-effective method of screening isolates with inhibitory activities for potentially novel activities. Further identification and characterization of the causative agents responsible for the inhibitory activities are required to confirm the novelty of an antibiotic.

The phyla of the prioritized isolates are known to make up a significant proportion of the active layer permafrost microbial community and are established secondary metabolite producers (Pathma et al., 2011; Wilhelm et al., 2011). Five out of the eight isolates that passed dereplication were *Pseudomonas* spp. This observation is not unexpected, as these Gram-negative heterotrophic \( \gamma \)-Proteobacteria are routinely isolated from soil samples using classical cultivation techniques such as the ones employed here (Sbrana et al., 2002). Additionally, the microbial community living in active layer permafrost within the vicinity
of the MARS has been found to contain 19.4% γ-Proteobacteria (Wilhelm et al., 2011).

The only isolate that passed dereplication pertaining to the phylum Bacteroidetes was Flavobacterium sp. GHHS.3.LBZX.4. Two Firmicutes (one Bacillus sp. and one Paenibacillus sp.) were also observed to inhibit all strains comprising the ARP. These two genera are well-documented secondary metabolite producers known to produce a plethora of antimicrobial compounds (Pathma et al., 2011; Caulier et al., 2019).

Interestingly, Paenibacillus sp. GHS.8.NWYW.5 and Pseudomonas sp. GHCE.5.JVZL.12 were the only isolates passing dereplication that were not derived from active layer permafrost. Paenibacillus sp. GHS.8.NWYW.5 was isolated from sediments of the Gypsum Hill saline spring (~8% salts) and Pseudomonas sp. GHCE.5.JVZL.12 was isolated from a gypsum cryptoendolith. Our current knowledge of high Arctic saline spring sediments and cryptoendoliths as potential reservoirs of secondary metabolites is very limited and thus this finding serves as an interesting starting point for future studies.

**Two Promising Isolates Inhibit the Growth of Foodborne and Clinically Relevant Pathogens**

After the antibiotic activity of all eight isolates that passed the dereplication assay was tested against foodborne and clinically relevant pathogens, Pseudomonas sp. AALPS.10.MNAAK.13 and Paenibacillus sp. GHS.8.NWYW.5 were identified to have a broad spectrum of antibacterial activity. Pseudomonas sp. AALPS.10.MNAAK.13 was found to have the broadest activity against clinically relevant pathogens; inhibiting the growth of both Gram-positive and Gram-negative pathogens including MRSA, A. baumannii, MSSA, E. faecium, and E. faecalis. Paenibacillus sp. GHS.8.NWYW.5 was capable of inhibiting all four foodborne pathogens tested in this study. It displayed inhibitory effects at 37°C and at 5°C against S. aureus, S. enterica, L. monocytogenes, and E. coli O157:H7 (Tables 5, 6). The zones of inhibition produced by these Arctic isolates were visually similar to ones produced by the environmental reference strain P. terrae NRRL B-30644 which was initially isolated from a Russian poultry production environment and documented to have inhibitory activity against the foodborne pathogen Campylobacter jejuni (Lohans et al., 2014). To confirm that the antagonistic activities observed during the initial co-culture assays were due to secreted bacterial biomolecules, promising isolates were selected for organic extraction and tested against the parental strains of the ARP. The organic extract of isolates Pseudomonas sp. AALPS.10.MNAAK.13, and Paenibacillus sp. GHS.8.NWYW.5 exhibited zones of clearance against E. coli ΔbamΔtolC BW25113. These observations coupled with our detection of secondary metabolite gene clusters within Arctic isolates’ genomes (Table 7), suggest that the inhibitory activities observed in this study arose from secreted antibacterial secondary metabolites. Ongoing testing is taking place to identify the causative agent(s) within the crude extracts and to determine their potency and spectrum of activity.

Interestingly, both of these Arctic isolates displayed antibacterial activity against MRSA and MSSA. MRSA's prevalence and the number of deaths it causes yearly qualify this pathogen as a major global public health concern (Martin et al., 2019), and antibacterial activity against MRSA is therefore of particular interest. The recent discovery of malacidin (effective against MRSA and other Gram-positive pathogens) illustrates how natural products from soil-dwelling bacteria continue to represent promising drug leads for endemic antibiotic resistant pathogens of the 21st century (Hover et al., 2018). The secondary metabolites expressed by the Arctic isolates surveyed herein will be further characterized in future studies to determine if they have any chemotherapeutic potential.

The genome of Paenibacillus sp. GHS.8.NWYW.5 was found to 7 BGCs displaying low homology with clusters of its respective type strains of the same species. Conversely, all clusters detected within the genome of Pseudomonas sp. AALPS.10.MNAAK.13 displayed high homology when aligned with the type strain genome sequence. The genome of Paenibacillus sp. GHS.8.NWYW.5 featured the greatest number of total BGCs with five NRP clusters displaying low homology to its corresponding type strain genome. The type strain of this isolate, P. terrae NRRL B-30644 has been shown to express paenicidin and tridecaptin A1 (Lohans et al., 2014). Clusters encoding both paenicidin and tridecaptin were identified within the genome of Paenibacillus sp. GHS.8.NWYW.5, however, it was also found to encode five NRP clusters with low homology to the type strain genome. Follow-up experiments such as genome-wide transposon mutagenesis or targeted cloning and exogenous expression of specific clusters are required to determine which cluster(s) are responsible for the observed antibiotic activity exhibited by these isolates.

**Arctic Isolates That Passed the ARP Are Capable of Growth at Refrigeration Temperatures**

All isolates that passed the dereplication assay (except for Pseudomonas sp. GHCE.5.JVZL.12) were capable of growing at temperatures ≤ 0°C within 20 days of incubation and grew more quickly at room temperature. Only two isolates (Paenibacillus sp. GHS.8.NWYW.5 and Pseudomonas sp. GHCE.5.JVZL.12) were capable of growing at 37°C. This observation suggests that these isolates are eurypsychrophillic which are typically characterized by their tolerance to subzero temperatures and display optimal growth at ~20°C (Raymond-Bouchard et al., 2018). Previous studies conducted with similar soil samples from the MARS site have led to the isolation of eurypsychrophillic strains including Planococcus halocryophilus Or1 that is capable of growth at –15°C (Mykytczuk et al., 2016). The initial incubation of the bulk soil plates was performed at room temperature precluded the isolation of stenopsychrophiles which would have required lower cultivation temperatures (Raymond-Bouchard et al., 2018).

The antibacterial activity of Paenibacillus sp. GHS.8.NWYW.5 against foodborne pathogens at common household refrigeration temperatures makes it a promising candidate for biotechnological applications in food-safety. The use of cold-adapted
environmental strains as biopreservatives intended to inhibit the growth of foodborne pathogens within refrigerated commodities have been previously developed (Rovira and Melero, 2018). For example, certain strains of bacteriocin-producing *Carinobacteria* spp. isolated from natural environments have been used to limit the growth of pathogens within preserved seafood products (Wiernasz et al., 2017). The isolates identified in this study that were capable of subzero growth and displayed antibacterial activity at refrigeration temperatures could serve as interesting starting points for future food-safety applications.

**CONCLUSION**

The results of our bioprospecting demonstrate how crowdsourced classical microbial cultivation and cryo-iPlate cultivation contribute to a culture-dependent workflow that can lead to the identification of Arctic bacteria capable of antibacterial activity. First results suggest that the habitats within the vicinity MARS on Axel Heiberg Island harbor promising cold-adapted bacteria with antibacterial activities against both foodborne and clinically significant pathogens. Further investigation will be required to identify the causative agents responsible for the observed antibacterial activities and to explore potential clinical and food-safety applications.

**DATA AVAILABILITY**

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

**AUTHOR CONTRIBUTIONS**

EM carried out field work, lab work, analysis, and writing. MO carried out analysis, participated in experimental design, and contributed significantly to writing. TL and GM conducted the dereplication assay and screening against clinical pathogens. EH conducted the dereplication assay and participated in isolating and screening cryo-iPlate strains. JH and BB conducted whole genome sequencing and assembly. GA and OB-H assisted in isolating and screening cryo-iPlate strains. RL and DN advised in experimental design and writing. SG coordinated the MIMM212 undergraduate crowdsourcing laboratory course, and advised and contributed significantly to writing and analysis. LW supervised the project and significantly contributed to project design, writing and analysis.

**FUNDING**

This work was supported by the Fonds de recherche du Québec – Nature et technologies (FRQNT), Northern Scientific Training Program (NSTP), and Polar Continental Shelf Project (PCSP).

**ACKNOWLEDGMENTS**

We acknowledge the hard work of the students and teaching assistants that participated in the MIMM212 Laboratory in Microbiology in 2016 and 2017. We thank Dr. Gerry Wright for generously providing the ARP strains, and Adam Classen, Maria Lee Ai Lan, Dr. Sudhakar G. Bhandare from the laboratories of Dr. Jennifer Ronholm and Dr. Lawrence Goodridge for providing the foodborne pathogens. We also thank the laboratory of Dr. J. C. Vederas for supplying our team with *P. terrae* NRRL B-30644, and Samy Coulombe for assisting in designing the cryo-iPlate and for subculturing Arctic isolates.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2019.01836/full#supplementary-material

**REFERENCES**

Aziz, R. K., Bartels, D., Best, A. A., DeJongh, M., Disz, T., Edwards, R. A., et al. (2008). The RAST server: rapid annotations using subsystems technology. *BMC Genomics* 9:75. doi: 10.1186/1471-2164-9-75

Baker, D. D., Chu, M., Oza, U., and Raigarhia, V. (2007). The value of natural products to future pharmaceutical discovery. *Nat. Prod. Rep.* 24, 1225–1244.

Balabanova, L., Podvolotskaya, A., Slepchenko, L., Eliseikina, M., Noskova, Y., Nedashkovskaya, O., et al. (2017). Nucleolytic enzymes from the marine bacterium *Cobetia amphilecti* KMM 296 with antibiofilm activity and biopreservative effect on meat products. *Food Control* 78, 270–278. doi: 10.1016/j.foodcont.2017.02.029

Bitnun, A., and Yeh, E. A. (2018). Purpose of review the rise in antimicrobial resistance is an urgent public health threat which, in the absence of intervention, may result in a post-antibiotic era limiting the effectiveness of antibiotics to treat both common and serious infections. Globalization and human migration have profoundly contributed to the spread of drug-resistant bacteria. In this review, we summarize the recent literature. *Curr. Infect. Dis. Rep.* 20, 1–10. doi: 10.1007/s11908-018-0634-9

Blin, K., Shaw, S., Steinke, K., Villebro, R., Ziemert, N., Lee, S. Y., et al. (2019). antiSMASH 5.0: updates to the secondary metabolite genome mining pipeline. *Nucleic Acids Res.* 47, W81–W87. doi: 10.1093/nar/gkz310

Blin, K., Wolf, T., Chevrette, M. G., Lu, X., Schwalen, C. J., Kautsar, S. A., et al. (2017). antiSMASH 4.0—improvements in chemistry prediction and gene cluster boundary identification. *Nucleic Acids Res.* 45, W36–W41.

Boucher, H. W., and Corey, G. R. (2008). Epidemiology of methicillin-resistant *Staphylococcus aureus*. *Clin. Infect. Dis.* 46(Suppl. 5), S344–S349.

Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., et al. (2009). Bad bugs, no drugs: no ESKAPE! an update from the infectious diseases society of America. *Clin. Infect. Dis.* 48, 1–12. doi: 10.1086/595011

Brettin, T., Davis, J. J., Disz, T., Edwards, R. A., Gerdes, S., Olsen, G. J., et al. (2015). RASTtk: a modular and extensible implementation of the RAST algorithm for building custom annotation pipelines and annotating batches of genomes. *Sci. Rep.* 5:8365. doi: 10.1038/srep08365

Caulier, S., Nannan, C., Gillis, A., Licciardi, F., Bragard, C., and Mahillon, J. (2019). Overview of the antimicrobial compounds produced by members of the *Bacillus subtilis* group. *Front. Microbiol.* 10:302. doi: 10.3389/fmicb.2019.00302
Marcollefas et al. (2019). *Arctic Bacteria Displaying Antibacterial Activity*. *Frontiers in Microbiology* | www.frontiersin.org 16 August 2019 | Volume 10 | Article 1836

Cox, G., Sieron, A., King, A. M., De Pascale, G., Pawloski, A. C., Koteva, K., et al. (2017). A common platform for antibiotic dereplication and adjuvant discovery. *Cell Chem. Biol.* 24, 98–109. doi: 10.1016/j.chembiol.2016.11.011

Davis, E., Sloan, T., Aurelius, K., Barbour, A., Bodey, E., Clark, B., et al. (2017). Antibiotic discovery throughout the small world initiative: a molecular strategy to identify biosynthetic gene clusters involved in antagonistic activity. *MicrobiologyOpen* 6:e00435. doi: 10.1002/mbo3.435

Dhanesha, M., Nam, C. B., Krishnan, K., Sinha, R. K., Jayesh, P., Joseph, V., et al. (2017). Streptomyces arteriaeformis MCCB 248 isolated from Arctic fjord sediments has unique PKS and NRPS biosynthetic genes and produces potential new antibiotic natural products. *J. Biotech.* 7:32.

Doran, P. T. (1993). Sedimentology of Colour Lake, a nonglacial high Arctic lake, Axel Heiberg Island, NWT, Canada. *Arct. Alp. Res.* 25, 353–367.

Ferri, M., Ranucci, E., Romagnoli, P., and Giaccone, V. (2017). Antimicrobial resistance: a global emerging threat to public health systems. *Crit. Rev. Food Sci. Nutr.* 57, 2857–2876. doi: 10.1080/10408398.2015.1077192

Goodiard, J., Altschuler, J., Hindson, K., Chan-Y am, K., Marcolefas, E., and Whyte, L. G. (2017). In situ field sequencing and life detection in remote (79′ 26′ N) Canadian high arctic permafrost ice wedge microbial communities. *Front. Microbiol.* 8:2594. doi: 10.3389/fmicb.2017.02594

Gregory, A., Zayed, A., Conceição-Neto, N., Temperton, B., Bolduc, B., Alberti, A., et al. (2019). Marine DNA viral macro-and micro-diversity from pole to pole. *Cell 177*, 1109.e1–1112.e4. doi: 10.1016/j.cell.2019.03.040

Hover, B. M., Kim, S.-H., Katz, M., Charlop-Powers, Z., Owen, J. G., Ternei, M. A., et al. (2018). Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens. *Nat. Microbiol.* 3:415. doi: 10.1038/s41564-018-0110-1

Jang, K. H., Nam, S. J., Locke, J. B., Kauffman, C. A., Beatty, D. S., Paul, L. A., et al. (2013). Anthracmycin, a potent anthrax antibiotic from a marine-derived actinomycete. *Angew. Chem. Int. Ed.* 52, 7822–7824. doi: 10.1002/anie.201302749

Johannesson, K. H., and Lyons, W. B. (1995). Rare-earth element geochemistry of Colour Lake, an acid freshwater lake on Axel Heiberg Island, Northwest Territories, Canada. *Chem. Geol.* 119, 209–223. doi: 10.1016/0009-2541(94)00099-t

Kiessner, T., Bibb, M., Buttner, M., Chater, K., and Hopwood, D. (2000). Practical *Streptomyces* Genetics. Norwich: The John Innes Foundation.

Kim, D., Song, L., Breitwieser, F. P., and Salzberg, S. L. (2016). Centrifuge: rapid and sensitive classification of metagenomic sequences. *Genome Res.* 26, 1721–1729. doi: 10.1101/gr.210641.116

Klevens, R. M., Edwards, J. R., Tenover, F. C., McDonald, L. C., Horan, T., Goordial, J., Altshuler, I., Hindson, K., Chan-Y am, K., Marcolefas, E., and Whyte, L. G. (2016). Comparative transcriptomics of cold growth and adaptive features of a *Campylobacter jejuni* One polar flagellar strain. *PLoS One* 11:625.

Mitouva, M., Tutino, M. L., Infusini, G., Marino, G., and De Rosa, S. (2005). Exocellular peptides from Antarctic psychrophilic pseudomonadomonas haloplatikis. *Mar. Biotechnol.* 7, 523–531. doi: 10.1007/s11012-004-5098-2

Mykytczuk, N., Lawrence, J., Omelom, C., Southam, G., and Whyte, L. G. (2016). Microscopic characterization of the bacterial cell envelope of *Planococcus halocryophilus* Or1 during subzero growth at-15 C. *Polar Biol.* 39, 701–712. doi: 10.1007/s00300-015-1826-5

National Nosocomial Infections Surveillance System (2004). National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. *Am. J. Infect. Control* 32, 470–485. doi: 10.1016/j.ajic.2004.10.001

Nichols, D., Cahoon, N., Traktenberg, E., Pham, L., Mehta, A., Belanger, A., et al. (2010). Use of iChip for high-throughput in situ cultivation of “uncultivable” microbial species. *Appl. Environ. Microbiol.* 76, 2445–2450. doi: 10.1128/AEM.01754-10

Niederberger, T. D., Perreault, N. N., Tille, S., Lollar, B. S., Lacrampe-Couloume, G., Andersen, D., et al. (2010). Microbial characterization of a subzero, hypersaline methane seep in the Canadian High Arctic. *ISME J.* 4, 1326–1329. doi: 10.1038/ismej.2010.57

Orsi, W. D., Edghcomb, V. P., Christman, G. D., and Biddle, J. F. (2013). Gene expression in the deep biosphere. *Nature* 499:205. doi: 10.1038/nature12230

Overbeek, R., Olson, R., Pusch, G. D., Olsen, G. J., Davis, J. J., Disz, T., et al. (2013). The SEED and the rapid annotation of microbial genomes using subsystems technology (RAST). *Nucleic Acids Res.* 42, D206–D214.

Pathma, J., Rahul, G., Kamaraj, K., Subashri, R., and Sakthivel, N. (2011). Secondary metabolite production by bacterial antagonists. *J. Biol. Control.* 25, 165–181.

Pawar, S. V., Ho, J. C., Yadav, G. D., and Yadav, V. G. (2017). The impending renaissance in discovery & development of natural products. *Carr. Top. Med. Chem.* 17, 251–267. doi: 10.2174/156802661666616053015469

Perreault, N. N., Andersen, D. T., Pollard, W. H., Greer, C. W., and Whyte, L. G. (2007). Characterization of the prokaryotic diversity in cold saline perennial springs of the Canadian high Arctic. *Appl. Environ. Microbiol.* 73, 1532–1543. doi: 10.1128/aem.01759-06

Perreault, N. N., Greer, C. W., Andersen, D. T., Tille, S., Lacrampe-Couloume, G., Lollar, B. S., et al. (2008). Heterotrophic and autotrophic microbial populations in cold perennial springs of the high arctic. *Appl. Environ. Microbiol.* 74, 6989–6907. doi: 10.1128/AEM.00359-08

Perron, G. G., Whyte, L., Turnbaugh, P. J., Goodiard, J., Hanage, W. P., Dantas, G., et al. (2015). Functional characterization of bacteria isolated from ancient arctic soil exposes diverse resistance mechanisms to modern antibiotics. *PLoS One* 10:e0069533. doi: 10.1371/journal.pone.0069533

Pollard, W., Haltit, G., Whyte, L., Niederberger, T., Andersen, D., Omelom, C., et al. (2009). Overview of analogue science activities at the McGill Arctic research station, alex heiberg island, canadian high arctic. *Planet. Space Sci.* 57, 646–659. doi: 10.1016/j.pss.2009.01.008

Raymond-Bouchard, I., Tremblay, J., Altschuler, J., Greer, C. W., and Whyte, L. G. (2018). Comparative transcriptomics of cold growth and adaptive features of a eury- and steno-psychrophile. *Front. Microbiol.* 9:1565. doi: 10.3389/fmicb.2018.01565
Rovira, J., and Melero, B. (2018). "Protective cultures for the safety of animal-derived foods," in Probiotics and Prebiotics in Animal Health and Food Safety, eds D. Di Gioia and B. Biavati (Cham: Springer), 63–107. doi: 10.1007/978-3-319-71950-4_3

Sbrana, C., Agnolucci, M., Bedini, S., Lepera, A., Toffanin, A., Giovannetti, M., et al. (2002). Diversity of culturable bacterial populations associated to Tuber borchii ectomycorrhizas and their activity on T. borchii mycelial growth. FEMS Microbiol. Lett. 211, 195–201. doi: 10.1016/s0378-1097(02)00712-7

Schatz, A., Bugle, E., and Waksman, S. A. (1944). Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria.*, Proc. Soc. Exp. Biol. Med. 55, 66–69. doi: 10.3181/00379727-55-14461

Steven, B., Briggs, G., McKay, C. P., Pollard, W. H., Greer, C. W., and Whyte, L. G. (2007). Characterization of the microbial diversity in a permafrost sample from the Canadian high Arctic using culture-dependent and culture-independent methods. FEMS Microbiol. Ecol. 59, 513–523. doi: 10.1111/j.1574-6941.2006.00247.x

Tedesco, P., Maida, I., Palma Esposito, F., Tortorella, E., Subko, K., Ezeofor, C., et al. (2016). Antimicrobial activity of monoramnholipids produced by bacterial strains isolated from the Ross Sea (Antarctica). Mar. Drugs 14:E83. doi: 10.3390/md14050083

Tritt, A., Eisen, J. A., Facciotti, M. T., and Darling, A. E. (2012). An integrated pipeline for de novo assembly of microbial genomes. PLoS One 7:e42304. doi: 10.1371/journal.pone.0042304

van Belkum, M. J., Lohans, C. T., and Vederas, J. C. (2015). Draft Genome sequences of Paenibacillus polymyxa NRRL B-30509 and Paenibacillus terrae NRRL B-30644, strains from a poultry environment that produce tridecaptin A and paenicidins. Genome Announc. 3:e00372-15. doi: 10.1128/genomeA.00372-15

Vartoukian, S. R., Palmer, R. M., and Wade, W. G. (2010). Strategies for culture of ‘unculturable’ bacteria. FEMS Microbiol. Lett. 309, 1–7.

Waksman, S. A., and Woodruff, H. B. (1940). Bacteriostatic and bactericidal substances produced by a soil Actinomycetes. Proc. Soc. Exp. Biol. Med. 45, 609–614. doi: 10.3181/00379727-45-11768

Ward, D. M., Weller, R., and Bateson, M. M. (1990). 16S rRNA sequences reveal numerous uncultured microorganisms in a natural community. Nature 345:63. doi: 10.1038/345063a0

Wiernasz, N., Cornet, J., Cardinal, M., Pilet, M.-F., Passerini, D., and Leroy, F. (2017). Lactic acid bacteria selection for biopreservation as a part of hurdle technology approach applied on seafood. Front. Mar. Sci. 4:119. doi: 10.3389/fmars.2017.00119

Wilhelm, R. C., Niederberger, T. D., Greer, C., and Whyte, L. G. (2011). Microbial diversity of active layer and permafrost in an acidic wetland from the Canadian High Arctic. Can. J. Microbiol. 57, 303–315. doi: 10.1139/w11-004

Winterberg, H. (1898). Zur methodik der bakterienzählung. Z. Hyg. Infektionskr. 29, 75–93.

Yoon, S.-H., Ha, S.-M., Kwon, S., Lim, J., Kim, Y., Seo, H., et al. (2017). Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies. Int. J. Syst. Evol. Microbiol. 67, 1613–1617. doi: 10.1099/ijsem.0.001755

Zarins-Tutt, J. S., Barberi, T. T., Gao, H., Mearns-Spragg, A., Zhang, L., Newman, D. J., et al. (2016). Prospecting for new bacterial metabolites: a glossary of approaches for inducing, activating and upregulating the biosynthesis of bacterial cryptic or silent natural products. Nat. Prod. Rep. 33, 54–72. doi: 10.1039/c5np00111k

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Marcolefas, Leung, Okshovsky, McKay, Hignett, Hamel, Aguirre, Blenner-Hassett, Boyle, Lévesque, Nguyen, Gruenheid and Whyte. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.